Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, adaptive Phase 2 field study to evaluate the efficacy of a single SC dose of TNX-4800

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled, adaptive Phase 2 field study to evaluate the efficacy of a single SC dose of TNX-4800

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 26 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TNX 4800 (Primary)
  • Indications Lyme disease
  • Focus Therapeutic Use
  • Acronyms Field Study

Most Recent Events

  • 11 May 2026 According to a Tonix Pharmaceuticals media release,Company is looking forward to scheduled Type C meeting with the FDA early in the third quarter of 2026 to discuss the study.
  • 18 Apr 2026 New trial record
  • 31 Mar 2026 According to a Tonix Pharmaceuticals Holding Corp media release, the company expects to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study in the first half of 2027, pending FDA clearance

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top